After witnessing muted performances in the last few quarters, first on account of maize price issues affecting poultry vaccines and then the Covid related disturbances, the Q2 performance witnessed a substantial revival. Going ahead, opportunities panning out from PPR, Brucella vaccine tenders being floated in near term besides increased focus on health products, growth prospects looks promising for animal segment. That said, higher dependence on poultry segment and mostly tenderised nature of animal vaccine segment in the domestic market continue to influence...